In a typical managed care contract, which item is NOT usually included as a standard component?

In a typical managed care contract, which item is NOT usually included as a standard component?

• A. Payment terms (capitation or fee schedules) are included
• B. Network requirements are included
• C. Marketing exclusivity clause is not typically included
• D. Termination clauses are included

Answer: (C)

The main idea being tested is what elements are typically built into a standard managed care contract. In these agreements, you’ll usually see how the provider gets paid (capitation or fee schedules), what network participation requires (credentialing, in-network providers, access standards), and how the contract can be terminated if obligations aren’t met. These components directly support the contract’s core purpose: setting payment, defining the network, and outlining the lifecycle of the agreement. A marketing exclusivity clause is not a standard feature because it would restrict the provider’s ability to contract with other payers or to promote services to different populations. That kind of exclusivity can limit patient choice and raise competition and regulatory concerns, which is why it’s generally avoided in routine payer–provider contracts. It might appear only in specialized joint ventures or exclusive marketing arrangements, not as a standard element.

The main idea being tested is what elements are typically built into a standard managed care contract. In these agreements, you’ll usually see how the provider gets paid (capitation or fee schedules), what network participation requires (credentialing, in-network providers, access standards), and how the contract can be terminated if obligations aren’t met. These components directly support the contract’s core purpose: setting payment, defining the network, and outlining the lifecycle of the agreement.

A marketing exclusivity clause is not a standard feature because it would restrict the provider’s ability to contract with other payers or to promote services to different populations. That kind of exclusivity can limit patient choice and raise competition and regulatory concerns, which is why it’s generally avoided in routine payer–provider contracts. It might appear only in specialized joint ventures or exclusive marketing arrangements, not as a standard element.